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(100.3 and 99.6, respectively). ConClusions: Comorbidities, BMI, disease severity, 
and hospitalizations rates were stable over 3 years of follow-up for schizophrenia 
patients, an important finding for burden of schizophrenia disease assessment.
PMH7
CoMParing tHe influenCe of MontH of birtH and gender in two 
aCadeMiC years on attention defiCit HyPeraCtivity disorder 
diagnoses (adHd) aMong CHildren in tHe HealtH iMProveMent 
network (tHin) uk data
O’Leary C, Bourke A., Ansell D.
CSD Medical Research UK, London, UK
objeCtives: Long-term costs follow a diagnosis of ADHD; therefore it is important 
to examine factors influencing diagnosis. This study determines the prevalence of 
ADHD among children according to month of birth and gender across two academic 
years. Methods: Children aged 5-15 years in the academic years Sep 2010-Aug 
2011 (Year 1) and Sep 2011-Aug 2012 (Year 2) in The Health Improvement Network 
(THIN) were assessed for ADHD using diagnoses and prescriptions. Percentages were 
calculated and differences across month of birth assessed using chi squared tests 
for trend. Children with later months of birth (Mar-Aug) were compared to earlier 
months of birth (Sep-Feb), and males to females using relative risks (RR). Results: 
436,299 children in Year 1 and 398,718 in Year 2 were included with 0.75% and 0.76% 
diagnosed with ADHD respectively. There was evidence at the 5% level of an increas-
ing trend in ADHD prevalence in both academic years (p< 0.001, p= 0.005 in Year 
1, Year 2 respectively). Younger children were 14% more likely (RR= 1.14, 95% CI 
1.07-1.23) in Year 1 and 12% more likely (RR= 1.12 95% CI 1.04-1.20) in Year 2 to have 
ADHD than older children. Males were around five times more likely to have an 
ADHD diagnosis in both years (RR= 5.00 95% CI 4.56-5.49, RR= 4.92 95% CI 4.47-5.42 
in Year 1, Year 2 respectively). ConClusions: There was good agreement across 
academic years both in the percentage with ADHD diagnosis, and the increasing 
trend through the academic year. Younger children were more likely to be diagnosed 
with ADHD than their older peers. This may partly be due to them appearing to lack 
the maturity of their older classmates. Males were more likely to have an ADHD 
diagnosis than females in both years. Further work could assess the differences in 
different age groups and be extended to include other conditions.
PMH8
risk of deMentia assoCiated witH tHe use of Paroxetine aMong tHe 
elderly nursing HoMe Patients witH dePression
Bali V.1, Aparasu R.R.1, Johnson M.L.1, Chen H.1, Carnahan R.M.2
1University of Houston, Houston, TX, USA, 2University of Iowa, Iowa city, IA, USA
objeCtives: According to 2013 American Geriatrics Society Updated Beers Criteria, 
paroxetine has strong anticholinergic properties than other Selective Serotonin 
Reuptake Inhibitors (SSRIs). Such anticholinergic effects may lead to adverse cog-
nitive outcomes. This study examined the risk of dementia associated with the 
use of paroxetine versus other SSRIs. Methods: A retrospective cohort study 
was conducted using 2007-2010 Medicare claims data, and included nursing home 
residents > 65 years with depression. The study focused on incident SSRI users 
who did not have dementia in 2007 (baseline). Patients were included if they had 
continuous coverage for Medicare Parts A, B and D and no HMO coverage during 
the one year baseline and 2 years of follow up or until death. The primary outcome 
of this study was time to dementia diagnosis. SSRIs were classified as paroxetine 
and others. Cox proportional hazards regression was conducted to evaluate the risk 
of dementia with the use of paroxetine versus other SSRIs. Results: The study 
cohort consisted of 19,050 elderly nursing home residents with depression. Among 
SSRI users, 1,716 (9.01%) received paroxetine and 17,334 (90.99%) received others. 
Since proportional-hazard assumption was violated, the extended Cox hazard 
model involving Heaviside function was used to evaluate the dementia risk. The 
extended model revealed that paroxetine users had 66% [Hazards Ratio, HR, 1.66; 
95% Confidence Interval (CI), 1.03-2.67] higher risk for dementia than other SSRIs 
users after 390 days of treatment. However, the dementia risk did not vary within 
390 days of SSRI use. Other factors positively associated with dementia risk were age, 
male gender, and non-White race. ConClusions: Paroxetine use was associated 
with a time-varying increase in risk of dementia among depressed elderly nursing 
home residents. There is a need to optimize anticholinergic medication use in this 
population as depression is an independent risk factor for dementia.
PMH9
tHe effeCt of lurasidone on funCtional reMission aMong Patients 
witH biPolar dePression
Hassan M.1, Dansie E.2, Rajagopalan K.1, Wyrwich K.2, Loebel A.3, Pikalov A.1
1Sunovion Pharmaceuticals, Inc., Marlborough, MA, USA, 2Evidera, Bethesda, MD, USA, 
3Sunovion Pharmaceuticals, Inc., Fort Lee, NJ, USA
objeCtives: Bipolar depression is characterized by depressive symptoms and 
impairment in many areas of functioning, including work, family, and social life. 
There is continuing need for treatment options that provide remission in symp-
toms and functioning. The efficacy of lurasidone on symptom remission of bipo-
lar depression has been demonstrated previously. The objective of this study was 
to assess the effect of lurasidone on functional remission. Methods: Post-hoc 
analysis of a 6-week, randomized, double-blind, placebo-controlled clinical trial of 
lurasidone (20–60 mg or 80-120 mg) versus placebo was conducted. Functioning was 
measured using the Sheehan Disability Scale (SDS), a validated patient-reported 
outcome measure assessing functioning in terms of work/school, family, and social 
life (higher scores indicate lower functioning). Functional remission (defined as 
SDS total score ≤ 6) was compared between lurasidone and placebo groups using 
logistic regressions. Results: In this 6-week trial (N= 485), few participants were 
in functional remission at baseline (1.7%). The mean change in SDS total score from 
baseline to study endpoint was -10.4 (SD = 7.49) in the lurasidone group and -7.1 
(SD = 8.27) in the placebo group. A greater percentage of participants on lurasidone 
achieved functional remission in comparison to placebo (40.9% vs. 25.5%, p= 0.01) 
PMH4
adHerenCe to antidePressants is assoCiated witH lower Mortality: 
a four-year PoPulation-based CoHort study
Krivoy A.1, Balicer R.D.2, Feldman B.2, Hoshen M.B.3, Zalsman G.1, Weizman A.1, Shoval G.1
1Geha Mental Health Center, 2Clalit Health Services, Tel Aviv, Israel, 3Clalit Research Institute, Tel 
Aviv, Israel
objeCtives: Despite the growing use of antidepressants (AD) and the potential 
grave consequences of inadequate treatment, little is known about the impact of 
adherence to AD treatment on mortality in the general population. This study aimed 
to evaluate the association between adherence to AD and all-cause mortality in 
a population-based cohort. Methods: Data were extracted from the electronic 
medical database of the largest health provider in Israel, covering 53% of Israel’s 
population, and a total of 251,746 patients were included who had purchased AD 
at least once and were older than 40 years of age, between 2008-2011. Adherence 
was measured as mean possession ratio (duration of supplied AD divided by dura-
tion of prescribed AD) and was modeled as a four level variable: non-adherence 
(< 20%), poor (20%-50%), moderate (50% - 80%), and good (> 80%) adherence. We used 
survival analyses and included demographic and clinical variables to determine 
the adjusted association between AD adherence and mortality Results: The poor, 
moderate and good adherence groups had adjusted mortality hazard ratios of 0.93 
[95% Confidence interval (CI): 0.89 to 0.97], 0.83 [95% CI: 0.79 to 0.86] and 0.88 [95% 
CI: 0.85 to 0.91], respectively, with corresponding p-values < 0.0001 for all compari-
sons, compared to the non-adherent group. ConClusions: Adherence to AD, even 
at low levels, is associated with a corresponding decrease in the risk of mortality, 
controlling for relevant covariates. Physicians from all disciplines should actively 
improve their patients’ adherence to AD since their persistent use is associated 
with increased survival.
PMH5
findings of a retrosPeCtive study on faCtors resPonsible for 
dePression in india
Sachdeva M.1, Dhingra S.2, Parle M.3, Maharaj S.2
1Panjab University, Chandigarh, India, 2The University of the West Indies, St. Augustine, Trinidad 
and Tobago, 3Guru Jambheshwar University of Science and Technology, Hisar, India
objeCtives: Depression is a leading cause of morbidity and disability worldwide. 
The factors responsible for the prevalence of depression vary across countries 
and cultures. This study was aimed to provide data on the prevalence of depres-
sion and the possible risk factors responsible for its prevalence in Haryana State, 
India. Methods: A retrospective evaluation of the medical records was carried 
out at the psychiatric units of three different district government hospitals from 
September 2010 till August 2013. The data was analyzed by using the statistical 
software, SPSS version 13®. Results: The medical records of a total of 4512 patients 
with a confirmed diagnosis of depression were evaluated. The prevalence of depres-
sion was found to be significant among females (χ 2 = 32.9, df = 1, p< 0.001), as a 
majority (58 %) of the patients were females. In terms of ethnicity, seventy-eight 
percent patients were Hindus and mainly belonging to lower castes of community 
and other backward classes. However, in terms of age, majority, 1714 (38%) were 
over 50 years of age (χ 2 = 38.78, df = 1, p< 0.0001). Whilst evaluating the risk factors 
for depression, social problems and medical complications were the most common 
identified stressors during patient evaluation. Marital and family problems, followed 
by relationship/childhood problems and death of loved ones, were the frequent 
risk factors identified among females. However, financial and job related problems 
were the most common stressors identified among males. Among medical com-
plications, hypertension was most frequent ConClusions: Overall, the findings 
demonstrated a high rate of depression among people of low socioeconomic status 
and aged patients with medical complications.
PMH6
evolution of disease outCoMes in sCHizoPHrenia: results froM tHe 
“CoHort for tHe general study of sCHizoPHrenia (Cgs)” witH 3 years 
of follow-uP
Jalbert J.J.1, Rossignol M.2, Rouillon F.3, Astruc B.4, Benichou J.5, Abenhaim L.6,  
Grimaldi-Bensouda L.7
1LA-SER Analytica, New York, NY, USA, 2LA-SER, Paris, France, 3Centre Hospitalier Sainte-Anne, 
Paris, France, 4Eutelmed SAS, faculté de médecine Cochin Port-Royal, Paris, France, 5Centre 
Hospitalier Universitaire de Rouen, Unité Inserm 657, Rouen, France, 6LA-SER, London, UK,  
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objeCtives: To describe the evolution and effect of prognostic factors on psychiatric 
hospitalization rates in schizophrenia patients over 3 years using the Cohort for 
the General study of Schizophrenia (CGS), a cohort established to provide a better 
understanding of schizophrenia outcomes and epidemiology in France. Methods: 
Between 2005-2011, 96 psychiatric centers recruited 1,388 patients meeting the 
following criteria: aged 15-65 years, DSM-IV criteria for schizophrenia, and treated 
as outpatients or hospitalized ≤ 3 months. Data on sociodemographics, body mass 
index (BMI), comorbidities, psychotropic treatments, disease severity as per Clinical 
Global Impression [CGI] scores, Brief Psychiatric Rating Scale, Global Assessment of 
Functioning scale, suicidality risk and suicide, were collected at baseline and semi-
annually. Crude psychiatric hospitalization rates per 100 person-years were calcu-
lated yearly and over 3 years of follow-up. Results: At cohort entry, mean age was 
38.7 years, 68.9% were men, average maximum CGI score was 5.8, and 46.1% were 
hospitalized in the past year. During follow-up, somatic comorbidities (cardiovas-
cular, endocrine, and respiratory) were stable at < 5%. Mean BMI was 25.3 at cohort 
entry and after 3 years. Hospitalization rates were: 53.8 (95% CI: 49.9-57.8) the first 
year, 54.8 (95% CI: 50.5-59.4) the second year, and 52.9 (95% CI: 48.5-57.6) the third 
year. By age group, 3-year hospitalization rates followed a bimodal distribution: 80.3 
among patients aged 15-24 years, 58.9 for patients aged 25-34 years, 45.1 for patients 
aged 35-44 years, 59.0 for patients aged 45-54 years, and 39.1 for patients ≥ 55 years. 
Rates were associated with higher baseline CGI scores (82.7 for a score of 7 [high-
est score]), appointed legal guardianship (69.4), and moderate or high suicide risk 
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objeCtives: Poor adherence to antipsychotics in schizophrenia is common and 
associated with increased hospitalization risk, a key driver of increased costs of care. 
The objective was to evaluate the effectiveness of a patient-assisted medication 
adherence program (PAMAP) on psychiatric hospitalization rates among schizo-
phrenia patients treated with long-acting injectable risperidone (RLAI). Methods: 
Between 2009-2010, patients aged 18-65 years meeting DSM-IV criteria for schizo-
phrenia and treated with RLAI were recruited from 36 centers in France and followed 
for 1 year. The PAMAP consisted of calling patients 48 hours prior their scheduled 
RLAI injections and within 3 days of a missed appointment. Adherent centers 
applied PAMAP to ≥ 50% of injections. Adherent patients received ≥ 80% of their 
injections within 5 days of the scheduled date. Otherwise, patients and centers 
were non-adherent. Poisson regression was used to derive rate ratios (RR) compar-
ing psychiatric hospitalization rates among adherent and non-adherent patients 
and centers. Propensity scores were used to derive adjusted RRs. Results: Of 506 
recruited patients, 95.7% were followed up to 1 year (average age: 38.7; 64.6% males; 
60.4% hospitalized in the previous year). Overall hospitalization rate over follow-up 
was 32.5 per 100 person-years. Fifteen centers treating 243 patients and 21 centers 
treating 263 patients were adherent and non-adherent, respectively. Lower hospitali-
zation rates were associated with PAMAP (crude RR: 0.64 [95% CI: 0.44-0.93]; adjusted 
RR: 0.78 [95% CI: 0.47-1.27]). Nearly 75% of patients were adherent but adherence 
was not associated with disease severity nor with reduced hospitalization rates. 
The effect of PAMAP on hospitalizations rates was greater among non-adherent 
(adjusted RR: 0.45 [95% CI: 0.16-1.28]) than adherent patients (adjusted RR: 0.88 [95% 
CI: 0.51-1.53]). ConClusions: Adherence among schizophrenia patients partak-
ing in a PAMAP for RLAI was high. PAMAP may reduce psychiatric hospitalization 
risk for schizophrenia patients with problems adhering to long-acting injectable 
antipsychotics treatment regimens.
PMH13
evaluating tHe iMPaCt of Cannabis use on MetaboliC syndroMe 
using data froM tHe Continuous national HealtH and nutrition 
exaMination survey
Thompson C.A., Hay J.W.
University of Southern California, Los Angeles, CA, USA
objeCtives: Cannabis is the most commonly used illicit substance in the United 
States. Usage rates have climbed in recent years, underscoring the need for knowl-
edge regarding the effects of cannabis use on factors associated with chronic health 
problems, such as heart disease and diabetes mellitus. Some studies suggest that 
cannabis use is associated with improvements in weight, BMI, and insulin resist-
ance. Methods: Data on 4,267 persons from Continuous National Health and 
Nutrition Examination Survey (NHANES) from 2005 to 2010 was used to explore 
the relationship between cannabis use and factors of metabolic syndrome, includ-
ing fasting insulin, glucose, insulin resistance, hemoglobin A1c, triglycerides, HDL 
cholesterol, BMI, waist circumference, and blood pressure. These relationships were 
first estimated with ordinary least squares (OLS) models. Next, instrumental vari-
ables (IV) methods were utilized to test and account for the potential endogeneity 
of cannabis use in the models. The first IV models used sexual behavior variables 
as instruments for past and current use of cannabis. The second used past cannabis 
use as an instrument for current use. Results: OLS models show lower fasting 
insulin, insulin resistance, BMI, and waist circumference in past cannabis users 
compared to individuals who reported never having used cannabis. In the first 
IV model, the coefficients on cannabis use are mostly non-significant. When past 
cannabis use is an instrument for current use, the results for fasting insulin, insulin 
resistance, and fasting glucose are significant in the opposite direction from the 
OLS results. Durbin-Watson-Hausman tests provide evidence of endogeneity of can-
nabis use for some outcomes. ConClusions: Models of the relationship between 
cannabis and health should account for endogeneity. Results of two-stage least 
squares estimation are inconsistent with OLS results, challenging the robustness 
of findings that indicate a positive relationship between cannabis use and fasting 
insulin, insulin resistance, BMI, and waist circumference.
PMH14
risk of PsyCHosexual dysfunCtion between users of seleCtive 
serotonin reuPtake inHibitors and serotonin norePinePHrine 
reuPtake inHibitors
Shewale A.R., Shah A., Painter J.
University of Arkansas for Medical Sciences, Little Rock, AR, USA
objeCtives: Newer antidepressants selective serotonin reuptake inhibitors (SSRIs) 
and serotonin norepinephrine reuptake inhibitors (SNRIs) are the most commonly 
prescribed antidepressants. This is due mostly to their better side effect profile when 
compared to older drugs like tricyclic antidepressants (TCAs). However these classes 
are not completely bereft of side effects. Psychosexual dysfunction is a condition 
that occurs commonly among depressed patients. It has been shown to be associ-
ated with antidepressant. The objective of our study is to compare the incidence of 
psychosexual dysfunction between TCAs, SSRIs, and SNRIs. Methods: We used a 
cohort study design in an administrative claims database (2006-2013 Lifelink claims 
data) to compare the incidence of psychosexual dysfunction in TCAs, SSRIs, and 
SNRIs. Incidence was reported per 10,000 person-years. The Cox proportional hazard 
model was used to assess the risk of adverse events while adjusting for potential 
confounders. Results: A total of 269489 patients with an incident prescription 
for a TCA, SSRIs or SNRIs were identified and met the study inclusion criteria. They 
constituted a total of 682,657 person years. The unadjusted hazard ratio of incidence 
of psychosexual dysfunction in patients on SNRIs compared to SSRIs was 1.625 
(1.506-1.755). The results were consistent after adjusting for various covariates using 
the Cox proportional hazards model. The hazard ratio for the full model was 1.429 
(1.323-1.545) and for the reduced model with covariates identified using stepwise 
regression was 1.431(1.325-1.546). The directionality of covariates adjusted for in 
the analysis was consistent with current literature. ConClusions: SNRIs were 
associated with a greater risk of psychosexual dysfunction than SSRIs.
at week 6; the functional remission rate was similar for participants receiving lur-
asidone 20-60 mg and lurasidone 80-120 mg group (41.1% and 40.6%, respectively). 
Controlling for baseline SDS total score and study center, the adjusted odds ratio 
for functional remission among participants receiving lurasidone versus placebo 
was 3.96 (p< 0.01, 95% CI [1.72, 9.13]) in the 20-60 mg lurasidone group and 2.46 
(p= 0.52, 95% CI [1.12 - 5.43]) in the 80-120 mg lurasidone group. ConClusions: 
This post-hoc analysis of a lurasidone pivotal trial showed statistically significant 
improvement in functional remission within 6-week study duration among patients 
with bipolar depression treated with lurasidone compared to placebo.
PMH10
systeMatiC review of long-aCting injeCtables (lai) versus oral 
atyPiCal antiPsyCHotiCs (oa) on HosPitalization in sCHizoPHrenia
Lafeuille M.H.1, Cloutier M.1, Fortier J.1, Duh M.S.2, Fastenau J.3, Dirani R.3, Lefebvre P.1
1Groupe d’analyse, Ltée, Montréal, QC, Canada, 2Analysis Group, Inc., Boston, MA, USA, 3Janssen 
Scientific Affairs, LLC, Titusville, NJ, USA
objeCtives: The current study aimed at assessing the impact of LAIs versus OAs 
on hospitalizations among patients with schizophrenia by conducting a thorough 
systematic review of studies with different study designs and performing a meta-
analysis. Methods: Using the PubMed database and major psychiatric conference 
proceedings, a systematic literature review for 01/2000–07/2013 was performed to 
identify English-language studies evaluating schizophrenia patients treated with 
atypical antipsychotics. Studies reporting hospitalization rates as a percentage of 
patients hospitalized or as the number of hospitalizations per-person per-year were 
selected. A meta-analysis of the percentage decrease in hospitalization rates from 
baseline during treatment was conducted as a primary analysis. The secondary anal-
ysis was a meta-analysis of the absolute rate of hospitalization during follow-up. 
Pooled treatment-effect estimates were calculated using random-effect models. To 
account for differences in patient and study-level characteristics between studies, 
meta-regression analyses were used. Subset analyses further explored the hetero-
geneity across study designs. No adjustment was made for multiplicity. Results: 
Fifty-eight studies evaluating 25 arms (LAIs: 13 arms, 4,516 patients; OAs: 12 arms, 
23,516 patients) in the primary analysis and 78 arms (LAIs: 12 arms, 4,481 patients; 
OAs: 66 arms, 96,230 patients) in the secondary analysis were identified. Reduction 
in hospitalization rates for LAIs was 20.7 percentage points higher than that of 
OAs (random-effect estimates: LAIs= 56.2% vs OAs= 35.5%, P= 0.023). Controlling for 
patient and study characteristics, the adjusted percentage reduction in hospitaliza-
tion rates for LAIs was 26.4 percentage points higher than for OAs (95%CI: 3.3-49.5, 
P= 0.027). As for the secondary analysis, no significant difference between LAIs and 
OAs was observed (random-effect estimate: -8.6, 95%CI: -18.1-1.0, P= 0.077). Subset 
analyses across type of study yielded consistent results. ConClusions: Results 
of this meta-analysis including studies with both interventional and non-interven-
tional designs and using meta-regressions, suggest that LAIs significantly reduce 
hospitalization rates for schizophrenia patients compared to OAs.
PMH11
tHe tradeoff between internal and external validity in CoMParing 
tHe effeCtiveness of transCranial MagnetiC stiMulation (tMs) witH 
antidePressant drug tHeraPy in tHe treatMent of Major dePression 
using ProPensity sCore MetHods
Simpson A.N.1, Simpson K.N.1, Bonneh-Barkay D.2, Demitrack M.A.2, Brock D.G.2
1Medical University of South Carolina, Charleston, SC, USA, 2Neuronetics, Inc., Malvern, PA, USA
objeCtives: Transcranial magnetic stimulation (TMS) is FDA cleared for use in 
pharmacoresistant depression. Two sham-controlled trials have confirmed its 
efficacy and safety. However, TMS has not been directly compared to pharmaco-
therapy. Propensity score matching was used to compare the effectiveness of TMS 
to pharmacotherapy. Prospectively collected data from a pragmatic study of 305 
patients treated in routine practice with TMS were matched to patients from the 
Sequenced Treatment Alternatives to Relieve Depression (STAR*D) study. Methods: 
TMS patients were propensity-score matched to STAR*D patients on baseline char-
acteristics using a 1:1 greedy matching algorithm. An unequal drug resistance 
distribution in the two populations allowed only 222 patients to match well on 
the first attempt. A subsequent re-matching of the remaining TMS subjects to the 
full STAR*D control population was performed to produce a complete match. This 
“double-dipping” approach enabled a successful complete match for all 305 TMS 
patients. Results: The matched STAR*D and TMS populations were similar at base-
line. QIDS-SR outcomes at 6 weeks showed that the TMS group had a greater clinical 
improvement (P< 0.0001). At 6-weeks 53% of TMS patients had no or mild depres-
sion versus 38% for STAR*D (p= 0.0023). Sensitivity analysis was used to estimate 
the potential effects of any remaining selection biasing factors, and confirmed an 
unlikely impact on results. ConClusions: The varying distribution of the severity 
of baseline treatment resistance between the TMS and STAR*D populations made it 
impossible to achieve a complete match in the first matching attempt. Subsequent, 
“double-dipping” allowed tight matching on baseline variables. We accepted the 
risk to internal validity posed by the remaining selection bias or confounding and 
the small impact to variability due to non-independence, in exchange for gaining 
an increased external validity for this difficult to match group. Matching hard-to-
match groups requires a trade-off between risks to internal and external validity.
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